AngioDynamics (NASDAQ:ANGO – Get Rating) had its price objective lowered by Raymond James from $25.00 to $22.00 in a report released on Friday morning, Benzinga reports. Raymond James currently has a strong-buy rating on the medical instruments supplier's stock.
Separately, StockNews.com assumed coverage on AngioDynamics in a research report on Wednesday, October 12th. They set a hold rating on the stock.
Get
AngioDynamics alerts:
AngioDynamics Stock Down 4.0 %
ANGO opened at $14.57 on Friday. The company has a quick ratio of 1.30, a current ratio of 2.16 and a debt-to-equity ratio of 0.12. The firm has a market cap of $569.80 million, a P/E ratio of -17.55 and a beta of 0.66. AngioDynamics has a 52 week low of $11.71 and a 52 week high of $24.87. The business's fifty day simple moving average is $13.42 and its 200 day simple moving average is $17.83.
Hedge Funds Weigh In On AngioDynamics
Several large investors have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its position in AngioDynamics by 1.9% during the third quarter. BlackRock Inc. now owns 6,411,415 shares of the medical instruments supplier's stock worth $131,177,000 after buying an additional 117,895 shares during the period. Victory Capital Management Inc. raised its holdings in shares of AngioDynamics by 3.4% in the 2nd quarter. Victory Capital Management Inc. now owns 2,933,155 shares of the medical instruments supplier's stock worth $56,757,000 after purchasing an additional 96,263 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of AngioDynamics by 1.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,750,872 shares of the medical instruments supplier's stock worth $59,255,000 after purchasing an additional 46,173 shares during the period. Vanguard Group Inc. raised its holdings in shares of AngioDynamics by 1.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,589,323 shares of the medical instruments supplier's stock worth $52,977,000 after purchasing an additional 38,898 shares during the period. Finally, Polar Capital Holdings Plc raised its holdings in shares of AngioDynamics by 21.6% in the 1st quarter. Polar Capital Holdings Plc now owns 1,882,375 shares of the medical instruments supplier's stock worth $40,546,000 after purchasing an additional 334,649 shares during the period. 94.94% of the stock is currently owned by hedge funds and other institutional investors.
About AngioDynamics
(Get Rating)
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally.
Read More
- Get a free copy of the StockNews.com research report on AngioDynamics (ANGO)
- Why Wall Street Has Bullish Targets on Target Stock
- 3 Airline Stocks Taking Off in 2023
- What Macy's Guidance Means For Retail
- Fortinet Stock Price Bumpy, Here Is Why
- Apexigen Stock Soars After Analyst Rating, Is It Time to Buy?
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
